#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Monitoring and tailoring the P2Y12 ADP receptor blocker therapy


Authors: Tomáš Bolek;  Barbora Korpallová;  Lukáš Urban;  Jakub Marko;  Jakub Benko;  Dana Prídavková
Authors place of work: I. Interná klinika JLF UK a UN Martin, Slovenská republika
Published in the journal: Vnitř Lék 2020; 66(1): 51-58
Category:

Summary

P2Y12 ADP receptor blocker (ADPRB) treatment forms currently the basis of pharmacotherapy in acute coronary syndrome (ACS) patients, and in patients after percutaneous coronary interventions (PCI). However, nowadays, there are lots of data demonstrating an association between insufficient ADPRB on-treatment response and the risk of ischemic events, including stent trombosis, which is an uncommon but life-threatening complication in patients after PCI. High on-treatment platelet reactivity may be detected with several laboratory tests. Light transsmition aggregometry with ADP induction is so far considered to be a „golden standard“, and VASP (vasodilator stimulated phosphoprotein) phosphorylation assessement using flow cytometry is probably the most specific test for the assessment of insuficient platelet response. If high on-treatment platelet reactivity is detected, this phenomenon migh be overcome with increased ADPRB dosing, ADPRB switch (e.g. switch of clopidogrel to prasugrel), or with the addition of other antiplatelet agent. The administration of cangrelor – a new parenteral ADPRB – might be another perspective way how to overcome the phenomenon of insuficient ADPRB on-treatment response. The article summarizes current knowledge about the ADPRB resistance and the risk of ischemic events in patients undergoing PCI, the current approaches for the detection of this resistance, and summarizes the current approaches for overcoming this phenomenon.

Keywords:

percutaneous coronary intervention – personalized medicine – high on-treatment platelet reactivity – P2Y12 ADP blockers


Zdroje

1. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 7: 494–502. 

2. Samoš M, Šimonová R, Kovář F, et al. Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. Am J Emerg Med 2014; 5: 461–465.

3. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 5: 486–501.

4. Taubert D, Bouman HJ, van Werkum JW. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 21: 2249–2250.

5. Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097–1105.

6. Valgimigli M, Bueno H, Byrne RA, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery diseaseof the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213–260.

7. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306: 1215–1223.

8. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 20: 2420–2425.

9. Frontroth JP. Light transmission aggregometry. Methods Mol Biol 2013; 992: 227–240.

10. Madsen EH, Schmidt EB, Maurer-Spurej E, et al. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 2008; 19: 335–341.

11. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968–1977.

12. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333–339.

13. Velik-Salchner C, Maier S, Innerhofer P, et al. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study. Anesth Analg 2009; 108: 1747–1754.

14. Flechtenmacher N, Kämmerer F, Dittmer R, et al. Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate. AJNR Am J Neuroradiol 2015; 36: 1953–1958.

15. Liu L, Wong KS, Leng X, et al. CHANCE Investigators. Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE. Neurology 2015; 85: 1154–1162.

16. Fedor M, Samoš M, Šimonová R, et al. Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay. Clin Appl Thromb Hemost 2015; 4: 334–338.

17. Samoš M, Fedor M, Kovář F, et al. Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? Blood Coagul Fibrinolysis 2016; 2: 117–120.

18. Bolek T, Samoš M, Šimonová R, et al. Does Pantoprazole Affect the On-Treatment Platelet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers?-A Pilot Prospective Study. Am J Ther 2017; 2: e162–e166.

19. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer – comparison with two flow cytometric methods. Thromb Res 2007; 121: 249–258.

20. Velik-Salchner C, Maier S, Innerhofer P, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008; 107: 1798–1806.

21. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849–856.

22. Consuegra-Sánchez L, López-Palop R, Cano P, et al. Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays. J Thromb Haemost 2013; 2: 379–381.

23. Verdoia M, Barbieri L, Suryapranata H, et al. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. Platelets 2016; 27: 93–104.

24. Lundström A, Wallén H, von Arbin M, et al. Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. J Stroke Cerebrovasc Dis 2015; 10: 2348–2357.

25. Bernlochner I, Jaitner J, Fries V, et al. High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease. Vasa 2016; 45: 155–161. 

26. Shim CY, Yoon SJ, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 2009; 134: 351–355.

27. Pinto Slottow TL, Bonello L, Gavini R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009; 104: 525–530.

28. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101–1109.

29. Campo G, Fileti L, de Cesare N, et al. 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010; 56: 1447–1455.

30. Jang J, Lim J, Chang K, et al. A comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention. J Clin Lab Anal 2012; 26: 262–266.

31. Fifi JT, Brockington C, Narang J, et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013; 34: 716–720.

32. Nordeen JD, Patel AV, Darracott RM, et al. Clopidogrel Resistance by P2Y12 Platelet Function Testing in Patients Undergoing Neuroendovascular Procedures: Incidence of Ischemic and Hemorrhagic Complications. J Vasc Interv Neurol 2013; 6: 26–34.

33. Leunissen TC, Peeters Weem SM, Urbanus RT, et al. High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values. Eur J Vasc Endovasc Surg 2016; 52: 198–204.

34. Collet JP, Cuisset T, Rangé G, et al. ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100–2109.

35. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159–2164.

36. Bagai A, Peterson ED, McCoy LA, et al. Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. Am Heart J 2017; 187: 19–28.

37. Jung HJ, Sir JJ. Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance. J Invasive Cardiol 2011; 23: E15–E18.

38. Bouman HJ, van Werkum JW, Breet NJ, et al. A case-control study on platelet reactivity in patients with coronary stent thrombosis. J Thromb Haemost 2011; 9: 909–916.

39. Rajendran S, Parikh D, Shugman I, et al. High on treatment platelet reactivity and stent thrombosis. Heart Lung Circ 2011; 20: 525–531.

40. Gaglia MA, Torguson R, Pakala R, et al. Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 2011; 24: 529–534.

41. Fedor M, Šimonová R, Fedorová J, et al. Role of VASP phosphorylation assay in monitoring the antiplatelet therapy. Acta Medica Martiniana 2013; 13: 21–26.

42. Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8: 482–488.

43. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85–92.

44. Remková A, Janušicová A, Remko M. Is antiplatelet therapy always effective? Vnitř Lék 2012; 58: 904–914.

45. Cuisset T, Frere C, Quilici J, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res 2007; 120: 893–899.

46. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404–1411.

47. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630–1636.

48. Cuisset T, Frere C, Poyet R, et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 2010; 103: 39–45.

49. El Ghannudi S, Ohlmann P, Meyer N, et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. JACC Cardiovasc Interv 2010; 3: 648–656.

50. Zhang S, Lai X, Li W, et al. VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. Thromb Res 2014; 134: 1272–1277.

51. Ari H, Ozkan H, Karacinar A, et al. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol 2012; 157: 374–380.

52. Collet JP, Hulot JS, Anzaha G, et al. CLOVIS-2 Investigators. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011; 4: 392–402.

53. Choi H, Ryu J, Seo H, et al. Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? Int J Clin Pharm 2015; 37: 758–761.

54. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124: 1132–1137.

55. Diodati JG, Saucedo JF, Cardillo TE, et al. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Thromb Haemost 2014; 112: 311–322.

56. Valenti R, Marcucci R, Comito V, et al. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis). JACC Cardiovasc Interv 2015; 8: 1563–1570.

57. Park SD, Lee MJ, Baek YS, et al. Randomised trial to compare a protective effect of Clopidogrel Versus TIcagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial). EuroIntervention 2016; 12: e964–e971.

58. Yao G, Su G, Li K, et al. Comparative study of ticagrelor and clopidogrel in therapeutic effect of acute myocardial infarction patients undergoing percutaneous coronary intervention. Saudi J Biol Sci 2017; 24: 1818–1820.

59. Sardella G, Calcagno S, Mancone M, et al. Comparison of therapy with Ticagrelor, Prasugrel or high Clopidogrel dose in PCI patients with high on treatment platelet reactivity and genotype variation. TRIPLETE RESET trial. Int J Cardiol 2015; 194: 60–62.

60. Behr T, Kuch B, Behr W, et al. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clin Res Cardiol 2011; 100: 907–914.

61. Kim BK, Oh SJ, Yoon SJ, et al. A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention. Yonsei Med J 2011; 52: 717–726.

62. Ha SJ, Kim SJ, Hwang SJ, et al. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention. Coron Artery Dis 2013; 24: 690–697.

63. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011; 4: 403–410.

64. Cuisset T, Frere C, Quilici J, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008; 1: 649–653.

65. Akkus NI, Rajpal S, Agnani S. Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis. J Invasive Cardiol 2012; 24: 76–78.

66. Wessler JD, Saldana F, Giugliano RP. Bridging therapy after recent stent implantation: case report and review of data. Cardiovasc Revasc Med 2012; 13: 30–38.

67. Alexopoulos D, Pappas C, Sfantou D, et al. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives. J Cardiovasc Pharmacol Ther 2018; 23: 13–22.

68. Eisen A, Harrington RA, Stone GW et al. CHAMPION Investigators. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. Int J Cardiol 2018; 250: 49–55.

69. Selhorst G, Schmidtler F, Ott A, et al. Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis. Platelets 2018; 9: 1–7.

70. Alexopoulos D. Prasugrel resistance: fact or fiction. Platelets 2012; 23: 83–90.

71. Samoš M, Fedor M, Kovář F, et al. Prasugrel loading dose in diabetic patients with acute STEMI - Always sufficiently effective? Observation in two cases and review of current knowledge. Cor et Vasa 2014; 56: e388–e395.

72. Samoš M, Fedor M, Kovář F, et al. The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. J Diabetes Res 2016; 2016: 2909436.

73. Lemesle G, Schurtz G, Bauters C, et al. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost 2015; 13: 931–942.

74. Silvano M, Zambon CF, De Rosa G, et al. A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. J Thromb Thrombolysis 2011; 31: 233–234.

75. Fiore M, Horovitz A, Pons AC, et al. First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor. Platelets 2014; 25: 636-638.

76. Orban M, Riegger J, Joner M et al. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. Platelets 2012; 23: 395–398.

77. Musallam A, Lev EI, Roguin A. Stent thrombosis in a patient with high on-treatment platelet reactivity despite ticagrelor treatment. Eur Heart J Acute Cardiovasc Care 2015; 4: 85–87.

78. Ramotowski B, Żuk A, Budaj A. Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor. Kardiol Pol 2017; 75: 614.

79. Morgan KP, More RS, Chauhan A. The use of ticagrelor in a patient at increased risk of stent thrombosis resistant to multiple thienopyridines. Cardiology 2011; 119: 88–89.

Štítky
Diabetology Endocrinology Internal medicine

Článok vyšiel v časopise

Internal Medicine

Číslo 1

2020 Číslo 1
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#